BRCA1 | WCRF

The Way Forward Is Clearer, Together.

Each year, WCRF designs, funds, conducts, and publishes numerous clinical studies on the spectrum of women’s cancers. All our gynecologic oncology experts work with the belief that each new clinical trial carries the potential to fundamentally change the future of patients with women’s cancers.

Take a look at how WCRF has contributed to the field of gynecologic oncology.

Contraceptive Use and the Risk of Ovarian Cancer Among Women With a BRCA1 or BRCA2 Mutation

Women's Cancer Research Foundation

Jun 15
2 min

Contraceptive Use and the Risk of Ovarian Cancer Among Women With a BRCA1 or BRCA2 Mutation

Women with a BRCA1 and BRCA2 mutation have a higher lifetime risk of developing ovarian cancer.

0 comments

Cancer Risks Associated with BRCA1 and BRCA2 Pathogenic Variants

Women's Cancer Research Foundation

Apr 7
1 min

Cancer Risks Associated with BRCA1 and BRCA2 Pathogenic Variants

In a recent study, age-specific risk estimates of cancers, excluding breast and ovarian cancer, associated with pathogenic variants in...

0 comments

Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers

Women's Cancer Research Foundation

Mar 28
1 min

Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers

Women with a BRCA 1 or 2 mutation carriers have an increased risk of developing breast cancer and ovarian cancer. However....

0 comments

Oral Contraceptives May Reduce Risk of Ovarian Cancer in BRCA Carriers

Women's Cancer Research Foundation

Oct 22, 2021
1 min

Oral Contraceptives May Reduce Risk of Ovarian Cancer in BRCA Carriers

Analyses showed a longer duration of contraceptive use and more recent use were associated with a greater reduction in ovarian cancer risk.

0 comments

Risk of Late-Onset Breast Cancer in Genetically Predisposed Women

Women's Cancer Research Foundation

Oct 12, 2021
1 min

Risk of Late-Onset Breast Cancer in Genetically Predisposed Women

Germline mutations in breast cancer predispose women to develop this malignancy, but in woman 65+years, the risk is not well-defined.

0 comments

Drug Boosts Survival for Women with Advanced Ovarian Cancer

Women's Cancer Research Foundation

Aug 5, 2021
1 min

Drug Boosts Survival for Women with Advanced Ovarian Cancer

Lynparza (Olaparib), a targeted cancer therapy, has recently shown a meaningful survival benefit after 5 years.

0 comments

Endometrial Cancer Risk in Women Diagnosed with a Germline BRCA1 or BRCA2 Mutation

Women's Cancer Research Foundation

Apr 7, 2021
2 min

Endometrial Cancer Risk in Women Diagnosed with a Germline BRCA1 or BRCA2 Mutation

BRCA1 and BRCA2 are genes that produce proteins that help repair damaged DNA (a person’s unique genetic code).

0 comments